Dr. Lal PathLabs to acquire 70% stake in SN Genelab, strengthening its genomics expertise and expanding advanced diagnostic ...

SN Genelab’s testing capabilities could gain wider reach through Dr Lal's network over time, potentially boosting growth ...

Emkay Global Financial is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 2100 ...

Get all latest & breaking news on Dr Lal Pathlabs Ipo. Watch videos, top stories and articles on Dr Lal Pathlabs Ipo at moneycontrol.com.

Master Captial Services said that Zydus Life has witnessed a strong upward move after breaking above horizontal resistance on above average volumes, confirming a positive shift in price momentum.

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire 70% stake in Sn Genelab Private Limited for INR 2.0 billion on September 24, 2026. A cash consideration of INR 1.68 billion will be paid by ...

What's Dr Lal Pathlabs Ltd share price today. Get Dr Lal Pathlabs Ltd latest news on BSE/NSE stock price live updates, Dr Lal Pathlabs Ltd financial results and overview, Dr Lal Pathlabs Ltd stock ...

The ₹168 crore acquisition of a 70 per cent stake in SN Genelab is expected to strengthen Dr Lal's genomics expertise and ...

Dr Lal PathLabs’ Dubai subsidiary has acquired an 80% stake in Ghana’s Sunshine Healthcare, making it a step-down subsidiary ...

India's Dr Lal PathLabs posts higher first-quarter profit on healthy demand for tests Indian diagnostics firm Dr Lal PathLabs on Friday reported a rise in first-quarter profit, boosted by sustained ...

New Delhi, Sep 26 (PTI) Diagnostic services provider Dr Lal PathLabs Ltd on Saturday said its wholly owned subsidiary, Dr Lal ...